Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Dacarbazine |
Synonyms | |
Therapy Description |
Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle. Dacarbazine is FDA approved for melanoma (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Dacarbazine | Deticene | Biocarbazine R | Chemotherapy - Alkylating 18 | Deticene (dacarbazine) alkylates and cross-links DNA, which disrupts the cell-cycle. Dacarbazine is FDA approved for melanoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02678572 | Phase III | Dacarbazine Ipilimumab Melphalan Pembrolizumab | Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 1 |
NCT01132014 | Phase I | Bevacizumab Dacarbazine | Autologous OC-DC Vaccine in Ovarian Cancer | Completed | USA | 0 |
NCT04733183 | Phase II | Dacarbazine Dacarbazine + Onfekafusp alfa | Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma (FLASH) | Recruiting | ITA | FRA | ESP | DEU | 1 |
NCT01835145 | Phase II | Dacarbazine Temozolomide Cabozantinib | Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye | Completed | USA | CAN | 0 |
NCT06346067 | Phase III | LXH 254 + Trametinib Trametinib Dacarbazine Temozolomide | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Recruiting | USA | GBR | AUS | 0 |
NCT03070392 | Phase II | Dacarbazine Ipilimumab Pembrolizumab Tebentafusp | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 6 |
NCT02788201 | Phase II | Erlotinib Thiotepa Imatinib Dacarbazine Arsenic trioxide Idarubicin Mitomycin C Thioguanine Mercaptopurine Methotrexate Cladribine Epirubicin Gemcitabine Doxorubicin Bleomycin Etoposide Gefitinib Daunorubicin Lomustine Sorafenib Sunitinib Ifosfamide Asparaginase Ixabepilone Abiraterone Azacitidine Ruxolitinib Decitabine Axitinib Estramustine Floxuridine Lapatinib Carmustine Fludarabine Nilotinib Cisplatin Vismodegib Vandetanib Melphalan Busulfan Carboplatin Toremifene Crizotinib Dactinomycin Temsirolimus Vorinostat Romidepsin Fluorouracil Irinotecan Bortezomib Tamoxifen Topotecan Chlorambucil Pentostatin Eribulin Carfilzomib Vemurafenib Hydroxyurea Exemestane Vincristine Sulfate Dasatinib Mitoxantrone Vinblastine Cytarabine Tretinoin Clofarabine Teniposide Docetaxel Pazopanib Oxaliplatin Streptozocin Paclitaxel Bendamustine Mechlorethamine Mitotane | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | Completed | USA | 0 |
NCT06377566 | Phase II | Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine Gemcitabine Dacarbazine Doxorubicin Pembrolizumab Brentuximab vedotin Vinorelbine Vinblastine | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03016819 | Phase III | Anlotinib Dacarbazine | A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS) | Active, not recruiting | USA | ITA | GBR | ESP | 1 |
NCT06264180 | Phase III | Nab-paclitaxel Nivolumab + RP1 Paclitaxel Nivolumab and relatlimab-rmbw Nivolumab Dacarbazine Pembrolizumab Temozolomide | VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3) | Recruiting | USA | 0 |
NCT05987332 | Phase II | Dacarbazine Pembrolizumab Ipilimumab + Nivolumab Crizotinib + IDE196 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT01763164 | Phase III | Dacarbazine Binimetinib | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
NCT01693068 | Phase II | Dacarbazine Pimasertib | Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma | Completed | USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 4 |